Corporate overview
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company listed on the Toronto Stock Exchange for over 15 years. To maximize its long term value, Theratechnologies develops novel therapeutic products in order to bring them to market. The Company’s strategy is to focus on indications that meet the following criteria:
- Have a competitive edge over products currently marketed or in development
- Have a straightforward regulatory path and a manageable clinical program
- Be aimed at a speciality market where commercial rights can be retained
- Have the potential for attractive profit margins and a rapid payback on investment
Portfolio of products
Phase 3 clinical studies evaluating our lead-product, tesamorelin, for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy have now been completed. In order to obtain market approval for the treatment of this important aspect of HIV-associated lipodystrophy, a New Drug Application was filed with the U.S. Food and Drug Administration on May 29, 2009.
Moreover, two independent exploratory studies sponsored by the National Institutes of Health in the United States are evaluating the potential of tesamorelin for the treatment of growth hormone deficiency associated with abdominal obesity as well as for the treatment of pre-Alzheimer syndrome.
In October 2008, Theratechnologies concluded a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. As per this agreement, EMD Serono has an option to participate in the development and commercialization of tesamorelin in other potential indications.
In earlier stages of development, we are also working on other therapeutic compounds, the most advanced of which is in preclinical development and targets acute kidney injury.